AI summary · may contain errors
DVD-3E, a protease-activatable logic-gated T cell engager pro-drug, enables conditional IL-2 and TCR cosignaling in solid tumor models, producing potent antitumor responses without systemic toxicity.
- Open access
Moving in bioRxiv, Molecular Cancer Therapeutics, Cell Reports Medicine, Clinical Cancer Research, Nature Reviews Clinical Oncology, Journal for ImmunoTherapy of Cancer, Nature Immunology and PLOS Biology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
DVD-3E, a protease-activatable logic-gated T cell engager pro-drug, enables conditional IL-2 and TCR cosignaling in solid tumor models, producing potent antitumor responses without systemic toxicity.
AI summary · may contain errors
Germinal Multi designs and rescues antibodies that jointly optimize one paratope for multiple antigenic variants, yielding breadth against resistance-associated EGFR variants and distinct historical SARS-CoV-2 variants.
AI summary · may contain errors
Intranasal HA Stalk-Fc vaccination in mice provides significant protection against H1N1, H5N1, H6N2, and H9N2, with reduced viral replication in nasal turbinates and lungs.
AI summary · may contain errors
Multi-specific nanobody-Fc fusions targeting TcdB neutralize multiple clinically relevant Clostridioides difficile subtypes and improve CDI outcomes in mice, outperforming bezlotoxumab.
AI summary · may contain errors
The CHARGE prognostic index stratifies relapsed/refractory multiple myeloma patients receiving BCMA- or talquetamab T-cell engagers into three PFS risk groups, including a high-risk median PFS of 1.6 months.
AI summary · may contain errors
Affinity maturation of human neutralizing interferon-α autoantibodies broadens specificity across all 12 IFN-αs, with epitope classes and synergy linked to IFN-α signaling blockade.
AI summary · may contain errors
DELPHI, an open antibody developability prediction platform, achieves mean AUC 0.959 for polyreactivity and 0.933 for SEC using CDR H3-cluster cross-validation.
AI summary · may contain errors
Early plasmablast-derived human monoclonal antibodies from primary mRNA vaccination show potent spike RBD/NTD neutralization, but variant-associated mutations more often impact antibodies to immunodominant regions than those targeting a conserved NTD hydrophobic pocket.
AI summary · may contain errors
BCR-MERFISH accurately identifies plasma cell V gene usage and clonality in mice, including settings with restricted or native plasma cell diversity, enabling in situ receptor profiling.
AI summary · may contain errors
Structural information from IgH CDR1–3 plus antibody isotype identifies antigen-specific B cell receptor groups in bulk IgH data, improving food allergen prediction and matching HIV prediction performance.
AI summary · may contain errors
Mirvetuximab soravtansine, an FRα-targeting antibody-drug conjugate, has regulatory approval for platinum-resistant ovarian cancer, marking a major clinical milestone for FRα-directed therapy.
AI summary · may contain errors
Conditional biologics engineered to activate in response to tumour-associated signals or within the tumour microenvironment are proposed to uncouple efficacy from toxicity in cancer immunotherapy.
AI summary · may contain errors
A panel of 19 human monoclonal antibodies neutralizes clade 2.3.4.4b H5N1 and maps five partially overlapping antigenic regions on H5 hemagglutinin.
AI summary · may contain errors
Protein therapeutic binders can be conditionally activated using masking moieties that prevent target binding until release by disease-linked stimuli like altered protease levels or pH.
AI summary · may contain errors
Downstream purification of next-generation biotherapeutics requires modality-specific separation strategies, because their structural and physicochemical differences create distinct manufacturing challenges beyond mAb expertise.
AI summary · may contain errors
89Zr-CB307 PET shows selective accumulation in PSMA-positive metastatic castration-resistant prostate cancer lesions, with liver uptake (SUVmean 13.06 ± 2.68 at day 7) and no spleen or marrow uptake.
AI summary · may contain errors
Ifabotuzumab-PBD ADC is the most efficacious EphA3-targeted antibody-drug conjugate, showing highest in-vitro potency and the strongest tumour growth reduction and survival benefit in mice.
AI summary · may contain errors
GenSci143, a B7-H3 × PSMA-directed bispecific antibody-drug conjugate, produced profound tumor regression in prostate cancer xenograft models and showed superior antitumor activity versus competitor ADCs.
AI summary · may contain errors
ALS-RAP generated KO-validated antibodies for 33 ALS-associated proteins, characterizing 303 antibodies to produce a publicly available toolbox and protein expression resource.
AI summary · may contain errors
ADCE-T02, a tissue factor–targeting ADC with an average drug-to-antibody ratio of 4.5, shows strong preclinical efficacy and is well tolerated in nonhuman primates.
AI summary · may contain errors
AAV-delivered IGF2R-targeting GELYTACs mediate sustained depletion of circulating IgG in mice by routing IgG to lysosomal clearance and degradation.
AI summary · may contain errors
LMN-201, a spirulina-delivered four-component monoclonal protein cocktail for Clostridioides difficile infection, achieved 100% initial clinical cure (21/21) and 90.5% sustained cure through four weeks (19/21).
AI summary · may contain errors
In an ex vivo human B cell system, IgM BCR signaling limits IgM antibody-secreting cell differentiation and survival by suppressing IRF4 and PRDM1 and increasing apoptosis in plasmablasts.
AI summary · may contain errors
Microalgal systems are positioned as a promising route for industrial monoclonal antibody production, leveraging light-driven growth and low-cost media to enable significant scalability.
AI summary · may contain errors
[225Ac]Ac-Macropa-M16AB achieved complete remissions in MUC-16-positive ovarian and pancreatic ductal adenocarcinoma patient-derived xenografts, with 100% sustained CRs in high/medium expressers.
AI summary · may contain errors
EMB-01 given weekly at 1,600 mg showed a confirmed objective response rate of 12.5% in 48 heavily pretreated metastatic colorectal cancer patients.
Journals this month
Topics moving, week to 17 Nov 2026
By field